Let’s start up with the current stock price of Onconova Therapeutics Inc. (ONTX), which is $0.89 to be very precise. The Stock rose vividly during the last session to $0.9569 after opening rate of $0.94 while the lowest price it went was recorded $0.8801 before closing at $0.95.
Recently in News on April 1, 2021, Onconova Therapeutics Announces Enrollment in Second Cohort of Phase 1 Study with ON 123300 in China. Corporate Partner HanX Biopharmaceuticals enrolled third patient in 80 mg group. You can read further details here
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Onconova Therapeutics Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $1.9300 on 02/18/21, with the lowest value was $0.4350 for the same time period, recorded on 01/04/21.
Onconova Therapeutics Inc. (ONTX) full year performance was 220.66%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Onconova Therapeutics Inc. shares are logging -53.76% during the 52-week period from high price, and 369.44% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.19 and $1.93.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 10068780 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Onconova Therapeutics Inc. (ONTX) recorded performance in the market was 91.58%, having the revenues showcasing 91.58% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 222.30M, as it employees total of 11 workers.
Market experts do have their say about Onconova Therapeutics Inc. (ONTX)
During the last month, 0 analysts gave the Onconova Therapeutics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 0.7555, with a change in the price was noted +0.6334. In a similar fashion, Onconova Therapeutics Inc. posted a movement of +244.56% for the period of last 100 days, recording 41,298,570 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for ONTX is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Technical breakdown of Onconova Therapeutics Inc. (ONTX)
Raw Stochastic average of Onconova Therapeutics Inc. in the period of last 50 days is set at 20.18%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 2.86%. In the last 20 days, the company’s Stochastic %K was 23.08% and its Stochastic %D was recorded 32.52%.
Bearing in mind the latest performance of Onconova Therapeutics Inc., several moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 91.58%. Additionally, trading for the stock in the period of the last six months notably improved by 231.13%, alongside a boost of 220.66% for the period of the last 12 months. The shares increased approximately by -11.64% in the 7-day charts and went down by -4.75% in the period of the last 30 days. Common stock shares were driven by 91.58% during last recorded quarter.